ARFRP1 and neoplasm: In particular, we recovered favourable OS of CMS2 patients treated with cetuximab (Fig. 4a), if their tumours additionally carried chr20q amplifications, i.e., ARFRP1 (Fig. 4c; p = 0.01, HR = 0.32 [0.13–0.77], FDRcet < 0.1), TOP1 (Supplementary Fig. 15a; p = 0.01, HR = 0.34 [0.15–0.74], FDRcet < 0.1) and SRC (Supplementary Fig. 15b; p = 0.01, HR = 0.37 [0.17–0.78], FDRcet < 0.1).